Clinical trials: Salmonella Infection
Risk Reduction
Blood Donor CVD 5000
This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries.
- Trial name
- NCT03971669
- Testing
- Vivotif Typhoid Oral Vaccine
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Typhoid
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
This study is to investigate the safety, tolerability and immunogenicity of the typhoid fever vaccine candidate M01ZH09 manufactured at commercial scale, at a new manufacturing facility.
- Trial name
- NCT00679172
- Testing
- Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3)
- Where
- 3 sites in United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Vaccine Reaction, Anemia
Non-specific Effects of Vaccination on Mortality and Morbidity
It has long been recognized that the positive effects of vaccination on childhood mortality cannot be solely attributed to a decline in the disease targeted by the vaccine.
- Conditions
- Vaccine Reaction, Anemia, Malaria,Falciparum, Salmonella Bacteraemia
- Trial name
- NOVAC (NCT03176719)
- Testing
- Venipuncture
- Where
- Burkina Faso
- Volunteers
- 1,005 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Soil-transmitted Helminthiasis, Schistosomiasis
Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders
NIDIAG is an international collaboration on integrated diagnosis-treatment platforms, funded by the European Commission (EC). NIDIAG aims to develop an improved, patient-centred system for delivering primary health care in…
- Conditions
- Soil-transmitted Helminthiasis, Schistosomiasis, Strongyloidiasis, Shigellosis
- Trial name
- NIDIAGDigest (NCT02105714)
- Testing
- Stool culturing for pathogenic bacteria, Kato-Katz technique, Baermann technique
- Where
- 7 sites in Côte d’Ivoire, Indonesia and 2 more
- Volunteers
- 2,800 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Cholera, Typhoid
Studies of Immune Responses to Orally Administered Vaccines in Developing Country
The efficacy and immunogenicity of enteric vaccines have generally been found to be lower in children in the developed than in the developing countries.
- Trial name
- NCT01019083
- Testing
- Control, Zinc Sulphate, Albendazole and Secnidazole
- Where
- Bangladesh
- Volunteers
- 1,016 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Inflammation, Vaccine
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
The purpose of this study is to determine if adding dietary fiber, such as inulin, to a diet that does not have enough fiber would raise the levels of potentially beneficial bacteria, such as Bifidobacterium, in the gut.
- Conditions
- Inflammation, Vaccine, Intestinal Permeability, Typhoid Fever
- Trial name
- NCT04543877
- Testing
- Inulin, Maltodextrin, Ty21a Typhoid Fever Vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- USDA, Western Human Nutrition Research Center
Typhoid, Paratyphoid Fever
Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam
This study is part of International Vaccine Institutes (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00131820
- Testing
- Typhoid Vi vaccine, Hepatitis A (control)
- Where
- Vietnam
- Volunteers
- 100,742 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid
Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
This is a multicenter, randomized, observer-blinded, controlled, immune equivalence study of a multi-dose (MD) formulation with 2PE preservative of SK bioscience Vi-DT compared to single dose (SD) formulation without preservative…
- Trial name
- NCT04204096
- Testing
- Vi-DT (Multi-dose formulation), Vi-DT (Single dose formulation), Control Vaccine
- Where
- 4 sites in Philippines
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid
Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine
This is a Phase I, Randomized, observer-blinded, age de-escalating study. The study objectives are: 1. To evaluate the safety of 25 μg of Vi-DT typhoid conjugate vaccine administered at 0 and 4 weeks. 2.
- Trial name
- NCT02645032
- Testing
- Vi-DT, Typhim Vi®, VAXIGRIP®
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid
Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine
This is a randomized, observer-blinded Phase 2 study in healthy infants and toddlers 6-23 months of age at the time of the first vaccine dose.
- Trial name
- NCT03527355
- Testing
- Vi-DT, FluQuadri™, 0.9% sodium chloride isotonic solution
- Where
- Philippines
- Volunteers
- 285 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid, Paratyphoid Fever
Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China
This study is part of International Vaccine Institute (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00131833
- Testing
- Typhoid Vi vaccine, Meningococcal A (control)
- Where
- China
- Volunteers
- 96,468 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Enteric Fever Caused by Salmonella Enterica Serovar Paratyphi A
Understanding Paratyphoid Infection
Enteric fever is responsible for over 20 million illnesses and 200,000 deaths each year. S. Paratyphi A accounts for a substantial and increasing proportion of these cases, as high as 90% in some regions of Asia.
- Trial name
- NCT02100397
- Testing
- Salmonella enterica serovar Paratyphi A (strain NVGH308)
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Weight Gain, Anemia, Iron Deficiency
Egg Intervention During Pregnancy in Indonesia
The study consists of two arms: 1) intervention group using eggs as supplementary food given from 2nd trimester of pregnancy to birth, and 2) observational group of pregnant mothers.
- Conditions
- Weight Gain, Anemia, Iron Deficiency, Birth Weight, Birth Length
- Trial name
- PRECODE (NCT04694235)
- Testing
- Egg intervention
- Where
- Indonesia
- Volunteers
- 702 people, healthy volunteers welcome
- Sponsor
- SEAMEO Regional Centre for Food and Nutrition
Typhoid Fever
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
The purpose of this study is to evaluate the immunogenicity and the kinetics of the anti-Vi antibody response following secondary vaccination with the Novartis Vaccines Institute for Global Health (NVGH) Vi-CRM197 vaccine in…
- Trial name
- NCT01438996
- Testing
- NVGH Vi-CRM197
- Where
- Belgium
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Novartis
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
This trial is aimed to evaluate the safety and immunogenicity profiles of a new Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine.
- Trial name
- NCT01123941
- Testing
- Typherix, NVGH Vi-CRM197
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novartis
Typhoid Fever
Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers
This is a multicenter (at travel clinics), phase 4 observational prospective cohort study in healthy adult male and female travelers for whom typhoid vaccination with Vivotif is recommended, as per standard practice.
- Trial name
- NCT02391909
- Testing
- Vivotif
- Where
- United States
- Volunteers
- 855 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Typhoid
Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine
This is a Multicenter, observer-blinded, randomized, Active controlled, Phase 3 study in healthy 6 months to 45 years aged Nepalese at the time of the first vaccine dose. The study objectives are: I.
- Trial name
- NCT03933098
- Testing
- Test Vaccine Vi-DT Typhoid conjugate, Control Vaccine Typbar TCV®
- Where
- 4 sites in Nepal
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid Fever
Vellore Typhoid Vaccine Impact Trial
This cluster randomised trial will examine the impact of introducing TyphiBEV, a typhoid conjugate vaccine licensed in India, on the incidence of typhoid fever in a high burden urban setting in South India.
- Trial name
- VEVACT (NCT05500482)
- Testing
- Typhoid conjugate Vaccine
- Where
- India
- Volunteers
- 72,400 people, healthy volunteers welcome
- Sponsor
- Christian Medical College, Vellore, India
Vaccine-Preventable Diseases, Typhoid Fever
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
The goal of this clinical trial is to explore the coadministration of oral typhoid fever (Vivotif®) and cholera (Dukoral®) vaccines in healthy volunteers aged 18-65 years.
- Conditions
- Vaccine-Preventable Diseases, Typhoid Fever, Cholera
- Trial name
- NCT06104345
- Testing
- Oral typhoid fever vaccine, Oral cholera vaccine
- Where
- Finland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Diarrhea
Rifaximin for Prevention of Travellers' Diarrhea
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
- Trial name
- NCT00742469
- Testing
- Rifaximin
- Where
- Mexico
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.